Table 1 MSC products approved in different countries
From: Pharmacokinetic characteristics of mesenchymal stem cells in translational challenges
Product | Origin | Therapeutic disease | Approved time | Approved region |
|---|---|---|---|---|
Queencell | Autologous adipose tissue | Subcutaneous tissue injury | 2010 | Korea |
Cellgram | Autologous BM | Acute myocardial infarction | 2011 | Korea |
Cartistem | Allogeneic umbilical cord blood | Degenerative osteoarthrosis | 2012 | Korea |
Cupistem | Autologous adipose tissue | Crohn’s Disease, Perianal fistulae | 2012 | Korea |
Prochymal | Allogeneic BM | Graft-versus-host disease | 2012 | Canada, New Zealand |
TEMCELL | Allogeneic BM | Graft-versus-host disease | 2015 | Japan |
NeuroNata-R | Autologous BM | Amyotrophic lateral sclerosis | 2014 | Korea |
Stempeucel | Allogeneic BM | Critical limb ischemia, Angiitis | 2015, 2020 | European Union, India |
Stemirac | Autologous BM | Spinal cord injury | 2018 | Japan |
Alofisel | Allogeneic adipose tissue | Crohn’s Disease, Perianal fistulae | 2018, 2021 | European Union, Japan |
